Cargando…
Advances in Targeting Cancer-Associated Genes by Designed siRNA in Prostate Cancer
SIMPLE SUMMARY: Despite great advancements in early detection and therapeutic strategies, the 5-year survival rate for patients with metastatic prostate cancer remains low (i.e., ~30%). Targeting prostate cancer-associated genes has emerged as a promising treatment for this devastating disease. This...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761674/ https://www.ncbi.nlm.nih.gov/pubmed/33287240 http://dx.doi.org/10.3390/cancers12123619 |